New Weight-Loss drug GZR18 takes on wegovy in major trial
NCT ID NCT07150975
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times
Summary
This study tests a new injectable drug called GZR18 against the well-known weight-loss medication Wegovy (semaglutide) in 420 adults who are obese or overweight. The main goal is to see how much weight participants lose after 52 weeks of treatment. The trial is currently recruiting and is in Phase 3, the final stage before possible approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY/OVERWEIGHT IN ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.